Clinical trial NCT03988205: Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
Official title: The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Leukemia, Myeloid, Acute
Keywords: Acute Myeloid Leukemia
Outpatient
CPX-351
Vyxeos®
Leukemia
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
First posted: 2019-06-17
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-arm, single-site run-in phase (six subjects) followed by a multicenter continuation phase (114 subjects), Phase IV study. Eligible subjects will be receiving CPX-351 as their usual medical care administered according to FDA approval, as a condition for participation.

Detailed description: This is an open-label, non-randomized study of a non-drug intervention in subjects receiving CPX-351 as their usual medical care administered according to its FDA approval. The study intervention is the application of a prescribed outpatient care model, including a nurse teacher educational program and quality of life surveys for both subjects and caregivers, in subjects who meet medical and logistical criteria. Induction therapy and medical follow-up are performed without prophylactic admission to an inpatient facility.

Eligibility criteria: Inclusion Criteria:

1. Subjects with newly diagnosed acute myeloid leukemia who are eligible for treatment with CPX-351 therapy according to the FDA approval and indication: therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
2. Age ≥ 18 years
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 (or Karnofsky Performance Status equivalent of 70 or above).
4. Total bilirubin ≤ 3 mg/dL.
5. Creatinine clearance \> 30 mL/min by Cockcroft/Gault equation.
6. Adequate cardiac function, as assessed by ejection fraction( ≥50% for anthracycline therapy) via multiple-gated acquisition (MUGA) or echocardiogram.
7. Total white blood cell count of ≤ 20,000/µL on peripheral blood assessment (hydrea and/or leukapheresis allowed).
8. No evidence of active, uncontrolled infection.
9. No evidence of clinically significant disseminated intervascular coagulation (DIC)
10. No clinically significant abnormalities in core vital signs like heart rate, blood pressure or oxygenation which require inpatient evaluation or monitoring.
11. In the opinion of the enrolling physician, the subject is not at risk for clinically significant tumor lysis syndrome based on clinical assessment, complete blood count (CBC), comprehensive metabolic panel (CMP), uric acid, and lactate dehydrogenase (LDH).
12. In the opinion of the enrolling physician, no medical conditions that preclude the subject or the primary caregiver from transportation to and from the outpatient clinical care facility.
13. Both subject and the identified primary caregiver(s) signed informed consent.
14. In the opinion of the enrolling physician, there are no medical contraindications to outpatient induction and management.
15. Male subjects, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the followings:

    * Practice effective barrier contraception during the entire study period and through six months after the last dose of CPX-351, OR
    * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are not acceptable methods of contraception.)

Female subjects must meet one of the followings:

* Postmenopausal for at least one year before enrollment, OR
* Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
* If the subject is of childbearing potential (defined as not satisfying either of the above two criteria), she must agree to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through six months after the last dose of CPX-351, OR o Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are not acceptable contraception methods.)

Logistical Inclusion Criteria

1. The subject must be able to reside within approximately 45 minutes of the hospital where induction therapy is administered, during normal driving conditions (in the opinion of the enrolling physician), until count recovery or 60 days post-treatment, whichever comes first
2. The enrolling physician must verify and attest that the subject has a primary caregiver meeting all the following criteria:

   * Reside with the subject.
   * Be able to care for the subject full time or arrange to share full-time care with secondary caregivers.
   * Provide transportation.
   * Respond to clinical issues that arise.
   * Communicate with subject and physician in a timely manner.
3. The nurse teacher must verify that the subject and primary caregiver have completed and adequately understand the study-dictated nurse teacher educational program.
4. The nurse teacher must verify the subject and primary caregiver have capacity to comply with outpatient management program.
5. The subject must have reliable, working telephone access.
6. The subject must be willing and able to attend all protocol-dictated visits and be seen frequently as an outpatient at the clinical care facility where induction therapy is administered.

Exclusion Criteria:

1. Pregnant women (per pregnancy test in women of childbearing potential) or women who are breast-feeding.
2. Subjects currently receiving any investigational agents.
3. Subjects must not have current evidence of another malignancy that requires treatment.
4. Subjects diagnosed with Wilson's disease and/or copper-related metabolic disorders.

Primary outcomes:
measure: Number of Participants Adherent to Recommendations
timeFrame: Day 60
measure: Number of Participants Adherent to Readmission Recommendations
timeFrame: Day 60
Secondary outcomes:
Other outcomes:
Locations:
city: Milwaukee
country: United States
facility: Froedtert Hospital
state: Wisconsin
Study officials:
affiliation: Medical College of Wisconsin
name: Laura Michaelis, MD
role: PRINCIPAL_INVESTIGATOR
References: